Document is current

Any future updates will be listed below

The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s12957-025-04150-0

Published Online: 2025-12-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark